Tag: group

PARIS, June 16, 2026 /PRNewswire/ -- In 2025, the global recorded music market reached $31.7 billion (IFPI), with streaming accounting for 69.6% and driving...

ABU DHABI, UAE, June 16, 2026 /PRNewswire/ -- Agthia Group PJSC, the region's leading food and beverage company, today announced the launch of Fuell, the...

BEIJING, June 16, 2026 /PRNewswire/ -- A report from China Daily ...

HONG KONG, June 16, 2026 /PRNewswire/ -- XTransfer, the world's leading B2B cross-border trade payment platform, is proud to announce that it has been...

They faced everything Everest could throw at them: bone-deep cold, unstable ice in the notorious Khumbu Icefall, and the shadow of tragedy that hung...

They faced everything Everest could throw at them: bone-deep cold, unstable ice in the notorious Khumbu Icefall, and the shadow of tragedy that hung...

MUMBAI, India, June 16, 2026 /PRNewswire/ -- InCred Capital, the institutional, wealth and asset management arm of InCred Group, today announced the launch of...

AS LHV Group’s May financial results reflected positive performance, with the results of all subsidiaries in line with the financial plan. LHV Group earned a consolidated net profit of EUR 9.1 million in May, with return on equity attributable to shareholders of 14.1%. Among the subsidiaries, AS LHV Pank earned EUR 9.8 million, LHV Bank Ltd EUR 0.3 million, AS LHV Varahaldus EUR 0.2 million and AS LHV Kindlustus EUR 0.4 million in net profit.

REYKJAVIK, Iceland , June 16, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the pricing of its previously announced underwritten public offering (the “Offering”) of 22,666,667 of its ordinary shares at an offering price of $3.75 per share. All ordinary shares to be sold in the Offering will be offered by Alvotech. The Offering is expected to close on or about June 17, 2026, subject to satisfaction of customary closing conditions. The Company has also granted the underwriters a 30-day option to purchase up to an additional 3,400,000 ordinary shares at the public offering price, less underwriting discounts and commissions. Before deducting the underwriting discounts and commissions and offering expenses, the Company expects to receive total gross proceeds of approximately $85 million from the Offering, or approximately $98 million if the underwriters exercise in full their option to purchase additional shares.

SYDNEY, June 15, 2026 /PRNewswire/ -- Bifox Limited ("Bifox") is pleased to advise it has entered into two agreements with Fossal S.A.A ("Fossal"), to...